No Data
No Data
Guangdong Zhongsheng Pharmaceutical Co., Ltd.'s (SZSE:002317) 8.8% Gain Last Week Benefited Both Individual Investors Who Own 55% as Well as Insiders
Guangdong Zhongsheng Pharmaceutical Gets Macau Patent Registration for Coronavirus Tablets
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Obtained the Macau OTC registration certificate for Lelulin, also known as Laiterpin.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as “Zhongsheng Ruichuang”), has obtained the registration certificate of a Class I innovative drug called Leluling from the Macau Special Administrative Region Government Pharmaceutical Supervision and Administration Bureau. Leluling is the world's first single peptide 3CL anti-new coronavirus drug with global independent intellectual property rights, independently developed by the company. It will be approved by the National Medical Products Administration in March 2023.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) holds approval for the production of vitamin B1 tablets, vitamin B2 tablets, vitamin B6 tablets, and vitamin C tablets.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) stated on the investor interaction platform on August 9 that the company holds approvals for batches of Vitamin B1 tablets, Vitamin B2 tablets, Vitamin B6 tablets, and Vitamin C tablets. The company's Vitamin B6 tablets are Class A medical insurance products, while its Vitamin C and Vitamin B1 tablets have been selected for the Common Chronic Disease Alliance Project in Guangdong Province.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) has not yet laid out in the field of cellular immunotherapy.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) stated on the investor interaction platform on August 6 that the company has not yet established a layout in cellular immunotherapy.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Its holding subsidiary has obtained the ethical approval for the phase II clinical trial of the class I innovative drug Oladiravir granules.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced on August 2nd that its controlling subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang"), recently received the approval letter for the clinical research project review of a class I innovative drug, Andrazeivir Granules (research and development code: ZSP1273 Granules), for the treatment of 2-17 year-old patients with uncomplicated type A influenza from the Clinical Research Ethics Committee of the Beijing Children's Hospital, the leading unit. The II phase clinical trial project is approved to be launched.
No Data